Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment

International Journal of Neuropsychopharmacology

Volumn 17, Issue 7, 2014, Pages 1095-1105

  Toteja, Nitin ^a   Gallego, Juan A ^a,b   Saito, Ema ^a   Gerhard, Tobias ^c,d   Winterstein, Almut ^e   Olfson, Mark ^f   Correll, Christoph U ^a,b,g,h  

^a Northwell Health   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adolescents; antipsychotics; attention deficit hyperactivity disorder; children; combination; disruptive behaviour disorders; paediatric; polypharmacy

Indexed keywords

NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT DISEASE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CHILDHOOD DISEASE; CONDUCT DISORDER; GROUPS BY AGE; HUMAN; OPPOSITIONAL DEFIANT DISORDER; OUTPATIENT DEPARTMENT; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TEACHING HOSPITAL; UNIVERSITY HOSPITAL; ADOLESCENT; CHILD; CLINICAL PRACTICE; MENTAL DISORDERS; PREVALENCE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; HUMANS; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PREVALENCE;

EID: 84901450562     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001320     Document Type: Review

References (55)

1. Biancosino B, Barbui C, Marmai L, Dona S, et al. (2006). Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. International Clinical Psychopharmacology 20, 305-309.
2. Bingefors K, Isacson D, Lindstrom E (2003). Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practice-a highly individualized therapy. Nordic Journal of Psychiatry 57, 263-269.
3. Castberg I, Spigset O (2008). Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit. Therapeutic Drug Monitoring 30, 597-603.
4. Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I, et al. (2008). Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. Journal of Child and Adolescent Psychopharmacology 18, 327-336.
5. Centorrino F, Goren JL, Hennen J, Salvatore P, et al. (2004). Multiple vs single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks vs benefits. American Journal of Psychiatry 161, 700-706.
6. Connor DF, Fletcher KE, Wood JS (2001). Neuroleptic-related dyskinesias in children and adolescents. Journal of Clinical Psychiatry 62, 967-974.
7. Constantine RJ, Boaz T, Tandon R (2010). Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large Medicaid program. Clinical Therapeutics 32, 949-959.
8. Correll CU (2008). Antipsychotic use in children and adolescents: minimising adverse effects to maximise outcomes. Journal of American Academy of Child and Adolescent Psychiatry 47, 9-20.
9. Correll CU, Frederickson AM, Kane JM, Manu P (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research 89, 91-100.
10. Correll CU, Gallego JA (2012). Correlates of antipsychotic polypharmacy. Psychiatric Clinics of North America 35, 661-681.
11. Correll CU, Kratochvil CJ, March J (2011). Developments in pediatric psychopharmacology: focus on stimulants, antidepressants and antipsychotics. Journal of Clinical Psychiatry 72, 655-670.
12. Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics-systematic review of 1-year studies. American Journal of Psychiatry 161, 414-425.
13. Correll CU, Manu P, Olshanskiy V, Napolitano B, et al. (2009b). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association 302, 1765-1773.
14. Correll CU, Rummel-Kluge C, Corves C, Kane JM, et al. (2009a). Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 35, 443-457.
15. Crystal S, Olfson M, Huang C, Pincus H, et al. (2009). Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs (Project Hope) 28, w770-w81.
16. Dean AJ, McDermott BM, Marshall RT (2006). Psychotropic medication utilisation in a child and adolescent mental health service. Journal of Child and Adolescent Psychopharmacology 16, 273-285.
17. dosReis S, Yesel Y, Rubin DM, Riddle MA, et al. ( 2011). Antipsychotic treatment among youth in foster care. Pediatrics 128, 1459-1466.
18. Elie D, Poirier M, Chianetta J, Durand M, et al. (2009). Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology 24, 37-44.
19. Faries D, Ascher-Svanum H, Zhu B, Correll C, et al. (2005). Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5, 26.
20. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, et al. (2000). Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. British Journal of Clinical Pharmacology 49, 80-86.
21. Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, et al. (2011). Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. European Neuropsychopharmacology 21, 621-645.
22. Gallego JA, Bonetti J, Zhang J, Kane JM, et al. (2012a). Prevalence and correlates of antipsychotic polypharmacy from the 1970s to 2009: A systematic review and meta regression. Schizophrenia Research 138, 18-28.
23. Gallego JA, Nielsen J, DeHert M, Kane JM, et al. (2012b). Safety and tolerability of antipsychotic polypharmacy. Expert Review on Drug Safety 11, 527-542.
24. Ganguly R, Kotzan JA, Miller LS, Kennedy K, et al. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 65, 1377-1388.
25. Gilmer TP, Dolder CR, Folsom DP, Mastin W, et al. (2007). Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatric Services 58, 1007-1010.
26. Goodwin G, Fleischhacker W, Arango C, Baumann P, et al. (2009). Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. European Neuropsychopharmacology 19, 520-532.
27. Hong IS, Bishop JR (2010). Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Annals of Pharmacotherapy 44, 1171-1180.
28. Hung GB, Cheung HK (2008). Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong. Hong Kong Medical Journal 14, 35-39.
29. Jerrell JM, McIntyre RS (2008). Adverse events in children and adolescents treated with antipsychotic medications. Human Psychopharmacology 23, 283-290.
30. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, et al. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry 188, 122-127.
31. Kelly DL, Love RC, Mackowick M, McMahon RP, et al. (2004). Atypical antipsychotic use in a state hospital 1104inpatient adoescent population. Journal of Child and Adolescent Psychopharmacology 14, 75-85.
32. Kogut SJ, Yam F, Dufresne R (2005). Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. Journal of Managed Care Pharmacy 11, 17-24.
33. Kreyenbuhl J, Marcus SC, West JC, et al. (2007). Adding or switching antipsychotic medications in treatment of refractory schizophrenia. Psychiatric Services 58, 983-990.
34. Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, et al. (2006). Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 84, 90-99.
35. Laita P, Cifuentes A, Doll A, Llorente C, et al. (2007). Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. Journal of Child and Adolescent Psychopharmacology 17, 487-501.
36. McCue RE, Waheed R, Urcuyo L (2003). Polypharmacy in patients with schziphrenia. Journal of Clinical Psychiatry 64, 984-989.
37. McIntyre RS, Jerrell JM (2008). Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives of Pediatrics and Adolescent Medicine 162, 929-935.
38. Messer T, Tiltscher C, Schmauss M (2006). Polypharmacy in the treatment of schizophrenia. Fortschritte der Neurologie-Psychiatrie 74, 377-391.
39. Morrato EH, Dodd S, Oderda G, Haxby DG, et al. (2007). Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clinical Therapeutics 29, 183-195.
40. Nielsen J, Dahm M, Lublin H, Taylor D (2010a). Psychiatrists' attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology 24, 965-971.
41. Nielsen J, le Quach P, Emborg C, Foldager L, Correll CU (2010b). 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatrica Scandinavica 122, 356-366.
42. Olfson M, Blanco C, Liu L, Moreno C, et al. (2006). National trends in the outpatiet treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 63, 679-685.
43. Olfson M, Blanco C, Liu SM, Wang S, et al. (2012). National trends in the office-based treatment of children and adolescents, and adults with antipsychotics. Archives of General Psychiatry 69, 1247-1256.
44. Pandurangi AK, Dalkilic A (2008). Polypharmacy with second-generation antipsychotics: a review of evidence. Journal of Psychiatric Practice 14, 45-367.
45. Pappadopulus E, Jensen PS, Schur SB, MacIntyre II JC, et al. (2002). 'Real World' Atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophrenia Bulletin 28, 111-121.
46. Patel NC, Hariparsad M, Matias-Akhtar M, Sorter MT, et al. (2007). Body mass indexes and lipid profiles in hospitalised children and adolescents exposed to atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology 17, 303-311.
47. Paton C, Lelliott P, Harrington M, Okocha C, et al. (2003). Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. Journal of Psychopharmacology 17, 223-229.
48. Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, et al. (2007). Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Current Medical Research and Opinion 23, 2815-2822.
49. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013). Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Current Opinion Psychiatry 26, 219-230.
50. Scotto Rosato N, Correll CU, Pappadopulos E, Chait A, et al. (2012). Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics 129, e1577-e1586.
51. Simeon J, Milin R, Walker S (2002). A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Progress in Neuro-psychopharmacology and Biological Psychiatry 26, 267-275.
52. Stahl SM, Grady MM (2004). A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry 11, 313-327.
53. Stahl SM, Grady MM (2006). High-cost use of secondgeneration antipsychotics under California's Medicaid program. Psychiatric Services 57, 127-129.
54. Wonodi I, Reeves G, Carmichael D, Verovsky I, et al. (2007). Tardive Dyskinesia in children treated with atypical antipsychotic medications. Movement Disorders 22, 1777-1782.
55. Zuddas A, Zanni R, Usala T (2011). Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. European Neuropsychopharmacology 21, 600-620.